Phagelux Overview
- Year Founded
-
2013
- Status
-
Private
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
9
- Investments
-
4
Phagelux General Information
Description
Developer of antibacterial products designed for human health, animal health, and crop sciences. The company's technology utilizes bacteriophage research to create targeted antibacterial products, providing healthcare providers and growers with biopesticides and treatments for pathogen control.
Contact Information
Website
www.phagelux.comCorporate Office
- Room 210018, Building 1, Baijiahui Innovation Community
- Number 699-18 Xuanwu Avenue, Xuanwu District
- Nanjing, Jiangsu
- China
Corporate Office
- Room 210018, Building 1, Baijiahui Innovation Community
- Number 699-18 Xuanwu Avenue, Xuanwu District
- Nanjing, Jiangsu
- China
Phagelux Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Phagelux Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Phagelux Patents
Phagelux Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3299459-A1 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
| EP-3299459-A4 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
| EP-3299459-B1 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
| EP-3312275-B1 | Antibiotic chimeric lyase from streptococcus and uses thereof | Active | 13-Apr-2015 | ||
| EP-3312275-A1 | Broad spectrum of streptococcus lyase and use thereof | Active | 13-Apr-2015 | A61K38/51 |
Phagelux Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Phagelux Investments & Acquisitions (4)
Phagelux’s most recent deal was a Later Stage VC with NexaBiome for . The deal was made on 15-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NexaBiome | 15-Mar-2021 | Later Stage VC | Biotechnology | ||
| Saisrui Microbial Technology | 14-Oct-2015 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| OmniLytics (Multi-line Chemicals) | 20-Jul-2015 | Merger/Acquisition | Biotechnology | ||
| Iveria Technologies (Novel Delivery Systems) | 23-Dec-2014 | Merger/Acquisition | Drug Delivery |
Phagelux Exits (1)
Phagelux’s most recent exit was on 15-Mar-2021 from NexaBiome. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| NexaBiome | 15-Mar-2021 | Completed |
|
Phagelux Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Saisrui Microbial Technology | Wuhan, China | 2013 | |
| OmniLytics (Multi-line Chemicals) | Sandy, UT | 1954 |
Phagelux FAQs
-
When was Phagelux founded?
Phagelux was founded in 2013.
-
Where is Phagelux headquartered?
Phagelux is headquartered in Nanjing, China.
-
What industry is Phagelux in?
Phagelux’s primary industry is Biotechnology.
-
Is Phagelux a private or public company?
Phagelux is a Private company.
-
What is Phagelux’s current revenue?
The current revenue for Phagelux is .
-
How much funding has Phagelux raised over time?
Phagelux has raised $10M.
-
Who are Phagelux’s investors?
Anhui Guokong Capital, BioSciKin, 120 Capital, Shuimu Capital, and Jingfeng (Beijing) Investment Fund Management are 5 of 11 investors who have invested in Phagelux.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
